Clinical trial
Clinical Study on the Efficacy and Safety of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-associated Hemophagocytic Lymphohistiocytosis After Allogeneic Hematopoietic Stem Cell Transplantation
NCT05532826 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Study on the Efficacy and Safety of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-associated Hemophagocytic Lymphohistiocytosis After Allogeneic Hematopoietic Stem Cell Transplantation
- Lead sponsor
- Beijing Friendship Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 8, 2022
- Completion date
- September 15, 2024
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic active epstein-barr virus infection, virus-associated hemophagocytic syndrome